NEWS
April 5, 2016
MedicalResearch.com | CEO Discusses Lorexys For Female Hypoactive Sexual Desire Disorder
February 19, 2016
Pharmaceutical Processing | In Development: HSDD Treatment for Women
February 19, 2016
PM360 | Will Lorexys Succeed Where Addyi Flopped?
December 8, 2015
S1 Biopharma and CKD Pharmaceuticals Announce Commercialization Agreement for Lorexys™ in South Korea for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Women
November 18, 2015
Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
November 18, 2015
Dr. Robert Pyke from S1 Biopharma to Present at ExL Pharma CNS Clinical Trial Forum
June 5, 2015
S1 Biopharma Supports FDA Advisory Committee’s Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
March 3, 2014
S1 Biopharma prepares to initiate Phase 2a Clinical Trial for Low Male Sexual Desire
August 19, 2013
The Scientist | Opinion: Sexual Dysfunction Matters
COMPANY
ABOUT US
MANAGEMENT
BOARD OF DIRECTORS
MEDICAL ADVISORY BOARD
SOCIAL MEDIA COMMUNITY GUIDELINES
PIPELINE
LOREXYS
OREXA
S1B-307
S1B-3006
R&D
SEXUAL DYSFUNCTION
HSDD in Women
HSDD in Men
Arousal Disorder and Orgasmic Disorder
CLINICAL TRIALS
Lorexys 1000 Study
Orexa Study
MEDICAL AFFAIRS
SCIENTIFIC PUBLICATIONS
PARTNERING
NEWSROOM
PRESS RELEASES
MEDIA COVERAGE
INVESTORS
LOGIN
CONTACT US
Upcoming Events